跳至主要内容
临床试验/ITMCTR2100004855
ITMCTR2100004855招募中1 期

A randomized, double-blind, controlled study on the treatment of stable vitiligo with compound Honghuabuji granules

Shanghai Dermatology Hospital0 个研究点开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 60(—)
性别
All

入选标准

  • 1. Patients who are clearly diagnosed as vitiligo, and those who have been diagnosed as blood stasis syndrome by Chinese medicine;
  • 2. Patients aged 18 to 60 years;
  • 3. Mainly confined and sporadic;
  • 4. In order to accurately compare the test results, the hypopigmented area of all patients in this test is <= 10% of the total body surface area;
  • 5. No systemic or topical glucocorticoid or immunosuppressant treatment or withdrawal of the drug for more than 3 months within 3 months;
  • 6. Patients with leukoplakia that have not expanded within 6 months and are in a stable phase;
  • 7. Patients who agree to take pictures of the skin lesions and can complete the treatment and follow-up on time.

排除标准

  • 1. Pregnant and lactating women;
  • 2. System or topical vitiligo drug treatment within 3 months;
  • 3. Patients who are allergic to tacrolimus ointment and compound Honghuabuji granules.
  • 4. Patients with severe heart, liver, kidney and other system diseases;
  • 5. Patients who withdraw halfway and have incomplete information.

研究者

发起方
Shanghai Dermatology Hospital

相似试验

A randomized, double-blind, controlled study on the... | 临床试验